https://www.harmreductionadvocate.com/educational-resources daily 0.75 2026-10-28 https://www.harmreductionadvocate.com/educational-resources/implementation-and-service-delivery monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d0fb3def-8d2c-447b-9f0e-ec49259c5a2a/study-1.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Korthuis PT, Cook RR, Gregoire D, et al. Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services. JAMA Netw Open. 2026;9(8):e2630608. https://doi.org/10.1001/jamanetworkopen.2026.30608 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c7ebbebf-d9f5-4a5c-8a9a-664944e07403/study-2.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Rucker JJ, Mantingh T, Kerr-Gaffney J, et al. Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial. Nat Med. 2026;32(9):3430-3437. https://doi.org/10.1038/s41591-026-04541-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/08c42cda-6309-4356-87e5-da2ca6b9d168/study-3.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Lewis BR, Hendrick J, Byrne K, et al. Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PLoS Med. 2025;22(9):e1004519. https://doi.org/10.1371/journal.pmed.1004519 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/77c1b65c-e1f0-438c-8b40-2ea49726e73c/study-4.png Educational Resources - Implementation and Service Delivery Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Dorval M, Audet-Croteau V, Chang SL, et al. Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation. Healthcare (Basel). 2026;14(11):1559. https://doi.org/10.3390/healthcare14111559 https://www.harmreductionadvocate.com/educational-resources/health-economics-and-coverage monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3aa0e50a-6521-489d-b224-986e0b8345b9/study-1.png Educational Resources - Health Economics and Coverage Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Marseille E, Mitchell JM, Kahn JG. Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial. PLoS One. 2022;17(2):e0263252. https://doi.org/10.1371/journal.pone.0263252 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/cf1f7ca0-fb09-470c-99f9-0382320a071e/study-2.png Educational Resources - Health Economics and Coverage Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Lebenbaum M, Mulsant B, Parikh SV, et al. Ketamine Versus Electroconvulsive Therapy for Nonpsychotic Treatment-Resistant Depression: A Cost-Effectiveness Analysis. Psychiatr Serv. 2026. https://doi.org/10.1176/appi.ps.20240407 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b196ff84-02db-4d09-a94c-2a28b22bf2c4/study-3.png Educational Resources - Health Economics and Coverage Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Chatterton ML, Perez JK, Thai T, et al. Economic evaluation of subcutaneous ketamine injections for treatment resistant depression: A randomised, double-blind, active-controlled trial - The KADS study. J Affect Disord. 2025;387:119502. https://doi.org/10.1016/j.jad.2025.119502 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c2b83b6f-a8e7-4f1b-ad69-057ed96e3410/study-4.png Educational Resources - Health Economics and Coverage Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: McCrone P, Fisher H, Knight C, et al. Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model. Psychol Med. 2023;53(16):7619-7626. https://doi.org/10.1017/s0033291723001411 https://www.harmreductionadvocate.com/educational-resources/equity-and-ethics monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5947ba7b-cd43-4a8f-9685-d146ab4b8780/study-1.png Educational Resources - Equity and Ethics Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hughes ME, Garcia-Romeu A. Ethnoracial inclusion in clinical trials of psychedelics: a systematic review. EClinicalMedicine. 2024;74:102711. https://doi.org/10.1016/j.eclinm.2024.102711 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/57807980-2c20-49a4-9798-5499d7d29b1f/study-2.png Educational Resources - Equity and Ethics Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Haft SL, Downey AE, Raymond-Flesch M, et al. A systematic review of participant diversity in psychedelic-assisted psychotherapy trials. Psychiatry Res. 2025;345:116359. https://doi.org/10.1016/j.psychres.2025.116359 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5f3a6032-414c-4f79-b735-4e0ff8d96d19/study-3.png Educational Resources - Equity and Ethics Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ham R, Gardner J, Carter A, Liknaitzky P. Participant Experiences of Therapeutic Touch in Psilocybin-Assisted Therapy. Brain Behav. 2026;16(2):e71262. https://doi.org/10.1002/brb3.71262 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/de5935ff-0a0a-4d9d-974a-f7f96bcacc34/study-4.png Educational Resources - Equity and Ethics Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Yu F, Tafur J, Moreno F, Dahmer S. Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization. Front Psychiatry. 2026;17:1777387. https://doi.org/10.3389/fpsyt.2026.1777387 https://www.harmreductionadvocate.com/educational-resources/public-health-and-prevention monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ce2b73e1-7b53-46cc-b4cf-0b1f3515f7fc/study-1.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Krebs TS, Johansen PØ. Psychedelics and mental health: a population study. PLoS One. 2013;8(8):e63972. https://doi.org/10.1371/journal.pone.0063972 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c062006a-1e22-40fc-9231-3fcbe01abf8d/study-2.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol. 2015;29(3):280-288. https://doi.org/10.1177/0269881114565653 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ef316afa-5f05-40c4-abf1-f1709de9a475/study-3.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kopra EI, Ferris JA, Winstock AR, Young AH, Rucker JJ. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. J Psychopharmacol. 2022;36(8):965-973. https://doi.org/10.1177/02698811221084063 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8c4341b1-488b-4e50-8c03-1c1671e80af3/study-4.png Educational Resources - Public Health and Prevention Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Montoy JCC, Wang RC, Coker AR, Smollin CG, Anderson BT. US Poison Center Encounters for Psilocybin-Related Exposures: 2013-2022. J Am Coll Emerg Physicians Open. 2025;6(5):100231. https://doi.org/10.1016/j.acepjo.2025.100231 https://www.harmreductionadvocate.com/educational-resources/safety-and-risk-management monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/72b8bce3-2c42-424d-ac23-4a9cfc95a783/study-1.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Becker AM, Holze F, Grandinetti T, et al. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. Clin Pharmacol Ther. 2022;111(4):886-895. https://doi.org/10.1002/cpt.2487 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8a6f5fde-75f1-4669-ad37-4d7e03696059/study-2.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hinkle JT, Graziosi M, Nayak SM, Yaden DB. Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2024;81(12):1225-1235. https://doi.org/10.1001/jamapsychiatry.2024.2546 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c113f453-9b55-432c-944e-954aa36d713f/study-3.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kopra EI, Ferris JA, Winstock AR, Young AH, Rucker JJ. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. J Psychopharmacol. 2022;36(8):965-973. https://doi.org/10.1177/02698811221084063 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/98ae991d-1645-4b0e-87e7-efd2c75bb741/study-4.png Educational Resources - Safety and Risk Management Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Evans J, Robinson OC, Argyri EK, et al. Extended difficulties following the use of psychedelic drugs: A mixed methods study. PLoS One. 2023;18(10):e0293349. https://doi.org/10.1371/journal.pone.0293349 https://www.harmreductionadvocate.com/educational-resources/drug-development-and-new-compounds monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3c7719fb-db16-41c1-ad75-35ab4f0c905e/study-1.png Educational Resources - Drug Development and New Compounds Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: James E, Erritzoe D, Benway T, et al. Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial. Front Psychiatry. 2023;14:1305796. https://doi.org/10.3389/fpsyt.2023.1305796 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/288556d4-5e28-448d-9ab9-49479341e694/study-2.png Educational Resources - Drug Development and New Compounds Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Rucker JJ, Roberts C, Seynaeve M, et al. Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants. J Psychopharmacol. 2024;38(8):712-723. https://doi.org/10.1177/02698811241246857 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/650e203d-3a15-48b9-b3d9-d7cb2a0c4aba/study-3.png Educational Resources - Drug Development and New Compounds Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. 2022;387(18):1637-1648. https://doi.org/10.1056/nejmoa2206443 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4fd86910-b6a5-417f-aec5-eeeca6ef6b1d/study-4.png Educational Resources - Drug Development and New Compounds Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Robison R, Barrow R, Conant C, et al. Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial. JAMA. 2025;334(15):1358-1372. https://doi.org/10.1001/jama.2025.13481 https://www.harmreductionadvocate.com/educational-resources/set-and-setting monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e91d23ba-f286-4c72-b14d-baff2c398033/study-1.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Strickland JC, Garcia-Romeu A, Johnson MW. Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy. ACS Pharmacol Transl Sci. 2021;4(2):472-478. https://doi.org/10.1021/acsptsci.0c00187 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c2c9b6d9-9d2f-4191-b389-30ede3c29228/study-2.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Studerus E, Gamma A, Kometer M, Vollenweider FX. Prediction of psilocybin response in healthy volunteers. PLoS One. 2012;7(2):e30800. https://doi.org/10.1371/journal.pone.0030800 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/aac118fb-4bed-4898-8688-ee975f06cff0/study-3.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Uthaug MV, Mason NL, Toennes SW, et al. A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats. Psychopharmacology (Berl). 2021;238(7):1899-1910. https://doi.org/10.1007/s00213-021-05817-8 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8cd2d28b-0cd3-4fcd-9e1e-7ed23879bb01/study-4.png Educational Resources - Set and Setting Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Estric C, Duron T, Kabani S, Lopez-Castroman J. Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review. J Psychopharmacol. 2025;39(9):910-929. https://doi.org/10.1177/02698811251338214 https://www.harmreductionadvocate.com/educational-resources/microdosing monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c8225393-5f26-4ad1-8412-9c0834157c36/study-1.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mueller L, Santos de Jesus J, Schmid Y, et al. Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(6):555-562. https://doi.org/10.1001/jamapsychiatry.2025.0044 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ddc57687-e24b-45ce-8179-189ac0972a21/study-2.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Murphy RJ, Sumner R, Evans W, et al. Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial. Biol Psychiatry. 2023;94(6):511-521. https://doi.org/10.1016/j.biopsych.2023.03.013 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9ccd3136-3c43-480b-8f62-8f6650e11547/study-3.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Polito V, Stevenson RJ. A systematic study of microdosing psychedelics. PLoS One. 2019;14(2):e0211023. https://doi.org/10.1371/journal.pone.0211023 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/49b68b3a-e76c-4a13-9837-778c842e6311/study-4.png Educational Resources - Microdosing Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Szigeti B, Kartner L, Blemings A, et al. Self-blinding citizen science to explore psychedelic microdosing. Elife. 2021;10:e62878. https://doi.org/10.7554/elife.62878 https://www.harmreductionadvocate.com/educational-resources/social-connection-and-relationships monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f30ebd1c-6f90-485a-ae1d-ae46d202c64d/study-1.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Jungwirth J, von Rotz R, Dziobek I, Vollenweider FX, Preller KH. Psilocybin increases emotional empathy in patients with major depression. Molecular psychiatry. 2025;30(6):2665-2672. https://doi.org/10.1038/s41380-024-02875-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3eb1ddfd-3d00-4f94-8466-b8f8be6690a8/study-2.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Watts R, Kettner H, Geerts D, Gandy S, Kartner L, Mertens L, et al. The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world. Psychopharmacology. 2022;239(11):3461-3483. https://doi.org/10.1007/s00213-022-06187-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0f425546-0134-4b29-8c82-3e216853eefe/study-3.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Danforth AL, Grob CS, Struble C, Feduccia AA, Walker N, Jerome L, et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology. 2018;235(11):3137-3148. https://doi.org/10.1007/s00213-018-5010-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1b4c3760-e4de-40e1-aa7e-bf7e5f9e7b4c/study-4.png Educational Resources - Social Connection and Relationships Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Monson CM, Wagner AC, Mithoefer AT, Liebman RE, Feduccia AA, Jerome L, et al. MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial. European journal of psychotraumatology. 2020;11(1):1840123. https://doi.org/10.1080/20008198.2020.1840123 https://www.harmreductionadvocate.com/educational-resources/creativity monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/901c09fb-3a74-48a3-b749-72dcb1c52207/study-1.png Educational Resources - Creativity Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mason NL, Kuypers KPC, Reckweg JT, et al. Spontaneous and deliberate creative cognition during and after psilocybin exposure. Transl Psychiatry. 2021;11(1):209. https://doi.org/10.1038/s41398-021-01335-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/23f8da2b-c3bf-4a41-b773-e020d67c8450/study-2.png Educational Resources - Creativity Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Wießner I, Falchi M, Maia LO, et al. LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking. J Psychopharmacol. 2022;36(3):348-359. https://doi.org/10.1177/02698811211069113 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d65019ad-aeab-4507-8dcb-8de5793ccfb7/study-3.png Educational Resources - Creativity Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mason NL, Mischler E, Uthaug MV, et al. Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being. J Psychoactive Drugs. 2019;51(2):123-134. https://doi.org/10.1080/02791072.2019.1580804 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2b266619-330b-41dd-8741-f4a05b451844/study-4.png Educational Resources - Creativity Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Prochazkova L, Marschall J, van Elk M, et al. Microdosing psilocybin and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials. Neuropharmacology. 2026;284:110732. https://doi.org/10.1016/j.neuropharm.2025.110732 https://www.harmreductionadvocate.com/educational-resources/personality-and-traits monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/90872f86-e181-4370-8f95-85927b075a29/study-1.png Educational Resources - Personality and Traits Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Weiss B, Ginige I, Shannon L, Giribaldi B, Murphy-Beiner A, Murphy R, et al. Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression. Psychological medicine. 2024;54(1):178-192. https://doi.org/10.1017/s0033291723001514 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/284752dd-ab0c-4745-a413-3ea50c1b3677/study-2.png Educational Resources - Personality and Traits Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Pagni BA, Zeifman RJ, Mennenga SE, Carrithers BM, Goldway N, Bhatt S, et al. Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial. The American journal of psychiatry. 2025;182(1):114-125. https://doi.org/10.1176/appi.ajp.20230887 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7c63ff5c-4f86-40ea-b895-aa1fa3b2a1c4/study-3.png Educational Resources - Personality and Traits Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Erritzoe D, Roseman L, Nour MM, MacLean K, Kaelen M, Nutt DJ, Carhart-Harris RL. Effects of psilocybin therapy on personality structure. Acta psychiatrica Scandinavica. 2018;138(5):368-378. https://doi.org/10.1111/acps.12904 https://www.harmreductionadvocate.com/educational-resources/inflammation-and-the-immune-system monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e4cce352-f7bc-4b18-bea8-09dcf3aa5e6f/study-1.png Educational Resources - Inflammation and the Immune System Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mason NL, Szabo A, Kuypers KPC, et al. Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study. Brain Behav Immun. 2023;114:299-310. https://doi.org/10.1016/j.bbi.2023.09.004 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fff6ffc6-3829-44be-b15f-8326f0a4555b/study-2.png Educational Resources - Inflammation and the Immune System Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Galvão-Coelho NL, de Menezes Galvão AC, de Almeida RN, et al. Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. J Psychopharmacol. 2020;34(10):1125-1133. https://doi.org/10.1177/0269881120936486 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/825e710b-9da6-4762-9ce2-f15ababdc565/study-3.png Educational Resources - Inflammation and the Immune System Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Low ZXB, Ng WS, Lim ESY, et al. The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies. Prog Neuropsychopharmacol Biol Psychiatry. 2025;136:111139. https://doi.org/10.1016/j.pnpbp.2024.111139 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/77daa31e-adb5-4c13-a19a-b4bd1460eaf4/study-4.png Educational Resources - Inflammation and the Immune System Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Qureshi O, Cowley J, Pegg A, et al. Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation? Br J Pharmacol. 2026;183(14):4006-4021. https://doi.org/10.1111/bph.70138 https://www.harmreductionadvocate.com/educational-resources/brain-imaging-research monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fb9349df-3782-43ef-b608-ab4b6b6303c8/study-1.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Wall MB, Demetriou L, Giribaldi B, Roseman L, Ertl N, Erritzoe D, et al. Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression. The American journal of psychiatry. 2025;182(6):569-582. https://doi.org/10.1176/appi.ajp.20230751 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b506bb6b-5316-4bcf-b474-bb37a0b4117e/study-2.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Siegel JS, Subramanian S, Perry D, Kay BP, Gordon EM, Laumann TO, et al. Psilocybin desynchronizes the human brain. Nature. 2024;632(8023):131-138. https://doi.org/10.1038/s41586-024-07624-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5f0851bf-568d-4b55-8db8-3caaf15b568b/study-3.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Timmermann C, Roseman L, Haridas S, Rosas FE, Luan L, Kettner H, et al. Human brain effects of DMT assessed via EEG-fMRI. Proceedings of the National Academy of Sciences of the United States of America. 2023;120(13):e2218949120. https://doi.org/10.1073/pnas.2218949120 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/97230cca-13b0-4562-95fc-903603d08e88/study-4.png Educational Resources - Brain Imaging Research Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbæk DS, Kristiansen S, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019;44(7):1328-1334. https://doi.org/10.1038/s41386-019-0324-9 https://www.harmreductionadvocate.com/educational-resources/premenstrual-dysphoric-disorder monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a0c01d7e-0ff7-472b-8595-901647dbaa4c/study-1.png Educational Resources - Premenstrual Dysphoric Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Nazareth M, Paone V, Yaden ME, et al. Cannabis, Psychedelics, and Other Substance Use to Manage Premenstrual Symptoms: A Survey Study. J Womens Health (Larchmt). 2026;35(10):994-1003. https://doi.org/10.1177/15409996261459360 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/30eaa168-6058-4d9f-9ac6-60d0c46622e7/study-2.png Educational Resources - Premenstrual Dysphoric Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Gukasyan N, Narayan SK. Menstrual Changes and Reversal of Amenorrhea Induced by Classic Psychedelics: A Case Series. J Psychoactive Drugs. 2024;56(1):50-55. https://doi.org/10.1080/02791072.2022.2157350 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4fce93d2-9dad-4b74-8acd-c1b20d8306b7/study-3.png Educational Resources - Premenstrual Dysphoric Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Fadiman J, Korb S. Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration. J Psychoactive Drugs. 2019;51(2):118-122. https://doi.org/10.1080/02791072.2019.1593561 https://www.harmreductionadvocate.com/educational-resources/pregnancy-and-postpartum monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2f7ad8f9-4251-4389-8fe2-d26e6d1bf9d8/study-1.png Educational Resources - Pregnancy and Postpartum Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Wang S, Deng CM, Zeng Y, et al. Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial. BMJ. 2024;385:e078218. https://doi.org/10.1136/bmj-2023-078218 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3e42e8ae-dfaa-42ab-85ef-fe8842eaff5f/study-2.png Educational Resources - Pregnancy and Postpartum Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Chen Y, Guo Y, Wu H, et al. Perioperative Adjunctive Esketamine for Postpartum Depression Among Women Undergoing Elective Cesarean Delivery: A Randomized Clinical Trial. JAMA Netw Open. 2024;7(3):e240953. https://doi.org/10.1001/jamanetworkopen.2024.0953 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7b96b705-453d-46d7-9eda-38fe48868bfd/study-3.png Educational Resources - Pregnancy and Postpartum Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ma JH, Wang SY, Yu HY, et al. Prophylactic use of ketamine reduces postpartum depression in Chinese women undergoing cesarean section. Psychiatry Res. 2019;279:252-258. https://doi.org/10.1016/j.psychres.2019.03.026 https://www.harmreductionadvocate.com/educational-resources/womens-health monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bacf578b-e564-48c7-9bbf-36d09978291d/study-1.png Educational Resources - Women’s Health Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Argento E, Strathdee SA, Tupper K, et al. Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting. BMJ Open. 2017;7(9):e016025. https://doi.org/10.1136/bmjopen-2017-016025 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/57106de6-9081-408b-b0f4-cce15acdb36a/study-2.png Educational Resources - Women’s Health Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Argento E, Goldenberg S, Deering K, et al. Interest in receiving psychedelic-assisted therapy among marginalized women: Implications and findings from a community-based study in Canada. Drug Alcohol Depend Rep. 2022;3:100044. https://doi.org/10.1016/j.dadr.2022.100044 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/545ada84-e3fd-47e8-90d8-1b3878175b11/study-3.png Educational Resources - Women’s Health Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Peck SK, Shao S, Gruen T, et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med. 2023;29(8):1947-1953. https://doi.org/10.1038/s41591-023-02455-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fb0530da-74c9-4eb5-ac3a-79b52f0bba7a/study-4.png Educational Resources - Women’s Health Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Han Y, Li P, Miao M, et al. S-ketamine as an adjuvant in patient-controlled intravenous analgesia for preventing postpartum depression: a randomized controlled trial. BMC Anesthesiol. 2022;22(1):49. https://doi.org/10.1186/s12871-022-01588-7 https://www.harmreductionadvocate.com/educational-resources/older-adults monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/dc5993d3-ad26-4dba-946d-45b3e3e25004/study-1.png Educational Resources - Older Adults Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Study 1. Low-dose LSD in 48 healthy older volunteers (Family, 2020) https://doi.org/10.1007/s00213-019-05417-7 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/999e594c-58d2-400a-aba6-52460e05a27b/study-2.png Educational Resources - Older Adults Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Study 2. Psilocybin therapy in 12 people with Parkinson’s disease (Bradley, 2025) https://doi.org/10.1038/s41386-025-02097-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0afbe1c9-bcfe-4ecc-9f52-0cc5d21f993e/study-3.png Educational Resources - Older Adults Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Study 3. Psilocybin-assisted group therapy in 18 older men who are long-term AIDS survivors (Anderson, 2020) https://doi.org/10.1016/j.eclinm.2020.100538 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0b91d01b-b98c-43f3-935d-f1c3d9695a84/study-4.png Educational Resources - Older Adults Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Study 4. Guided psychedelic group sessions in 62 older and 62 younger adults (Kettner, 2024) https://doi.org/10.1016/j.jagp.2024.05.007 https://www.harmreductionadvocate.com/educational-resources/veterans monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a28e1995-d1b7-409e-a907-d97eb112ce6f/study-1.png Educational Resources - Veterans Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mithoefer MC, Mithoefer AT, Feduccia AA, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018;5(6):486-497. https://doi.org/10.1016/s2215-0366(18)30135-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e8025003-92ba-4530-968e-fd93ef024b9f/study-2.png Educational Resources - Veterans Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Abdallah CG, Roache JD, Gueorguieva R, et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology. 2022;47(8):1574-1581. https://doi.org/10.1038/s41386-022-01266-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ca6b5ae1-1470-4cb6-b19b-6c287dd541ba/study-3.png Educational Resources - Veterans Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Cherian KN, Keynan JN, Anker L, et al. Magnesium-ibogaine therapy in veterans with traumatic brain injuries. Nat Med. 2024;30(2):373-381. https://doi.org/10.1038/s41591-023-02705-w https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c433beb2-852d-41ae-bdb9-2607be7807de/study-4.png Educational Resources - Veterans Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Armstrong SB, Levin AW, Sepeda ND, et al. Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial. Commun Med (Lond). 2026;6(1):411. https://doi.org/10.1038/s43856-026-01767-4 https://www.harmreductionadvocate.com/educational-resources/neurological-injury monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d07ff34f-4e42-452e-a659-de5a93706198/study-1.png Educational Resources - Neurological Injury Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Burman S, Chouhan RS, Kumar N, Mahajan C. Effect of Ketamine Analgosedation on Neurological Outcome in patients with Severe Traumatic Brain Injury: A Randomized Controlled Pilot Study. Neurocritical care. 2026;44(1):9-17. https://doi.org/10.1007/s12028-025-02274-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7f308cc6-d8af-47a7-8d1a-614724f2afb4/study-2.png Educational Resources - Neurological Injury Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Cherian KN, Keynan JN, Anker L, Faerman A, Brown RE, Shamma A, et al. Magnesium-ibogaine therapy in veterans with traumatic brain injuries. Nature medicine. 2024;30(2):373-381. https://doi.org/10.1038/s41591-023-02705-w https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ef29ee22-8d60-4dc4-b846-4fb4b20c9297/study-3.png Educational Resources - Neurological Injury Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Blest-Hopley G, Pasculli G, Ruffell SGD, Tsang W, Emmanuel O, Pate KM, et al. Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat. Frontiers in psychiatry. 2025;16:1594307. https://doi.org/10.3389/fpsyt.2025.1594307 https://www.harmreductionadvocate.com/educational-resources/traumatic-brain-injury monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/516a5da8-0e5a-4dd8-a3c2-e8e360cdc9fd/study-1.png Educational Resources - Traumatic Brain Injury Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Study 1. Ibogaine given with magnesium in 30 veterans with mostly mild traumatic brain injury (Cherian, 2024) https://doi.org/10.1038/s41591-023-02705-w https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c770295b-281b-4fd1-bd22-0183dc9f66ea/study-2.png Educational Resources - Traumatic Brain Injury Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Study 2. Psilocybin retreats in 21 veterans with a history of traumatic brain injury (Blest-Hopley, 2025) https://doi.org/10.3389/fpsyt.2025.1594307 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/597b5c97-f23a-4dbe-b7e5-3b0ccc4e2243/study-3.png Educational Resources - Traumatic Brain Injury Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Study 3. Views on psychedelic-assisted therapy in 21 service members and veterans with a history of traumatic brain injury (Gray, 2023) https://doi.org/10.1093/milmed/usac400 https://www.harmreductionadvocate.com/educational-resources/dementia-and-neurocognitive-disorders monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3999c6fa-2fc8-4962-b318-8c46cd439ee9/study-1.png Educational Resources - Dementia and Neurocognitive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Study 1. Low-dose LSD in 48 healthy older participants (Family, 2020) https://doi.org/10.1007/s00213-019-05417-7 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/34ca03d0-3253-4a16-bf6f-4ce42a4f5f62/study-2.png Educational Resources - Dementia and Neurocognitive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Study 2. Psilocybin therapy in 12 people with Parkinson’s disease and depression or anxiety (Bradley, 2025) https://doi.org/10.1038/s41386-025-02097-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c1c46a57-3a0a-44fa-920b-e1e9d3ce7310/study-3.png Educational Resources - Dementia and Neurocognitive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Kettner H, Roseman L, Gazzaley A, Carhart-Harris RL, Pasquini L. Effects of Psychedelics in Older Adults: A Prospective Cohort Study. Am J Geriatr Psychiatry. 2024;32(9):1047-1059. https://doi.org/10.1016/j.jagp.2024.05.007 https://www.harmreductionadvocate.com/educational-resources/parkinsons-disease monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e0f8cdd7-0a8c-4e91-a754-ed09239477cb/study-1.png Educational Resources - Parkinson’s Disease Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bradley ER, Sakai K, Fernandes-Osterhold G, et al. Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial. Neuropsychopharmacology. 2025;50(8):1200-1209. https://doi.org/10.1038/s41386-025-02097-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/60491dc1-12d8-40fa-96ed-47542213217a/study-2.png Educational Resources - Parkinson’s Disease Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Sherman SJ, Estevez M, Magill AB, et al. Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing l-DOPA-Induced Dyskinesias. Case Rep Neurol. 2016;8(1):53-58. https://doi.org/10.1159/000444278 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fbaf8e0b-bda4-4510-9424-54c834f4d953/study-3.png Educational Resources - Parkinson’s Disease Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Fleury V, Tomkova E, Catalano Chiuvé S, et al. Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report. J Parkinsons Dis. 2025;15(2):440-444. https://doi.org/10.1177/1877718x241312604 https://www.harmreductionadvocate.com/educational-resources/fibromyalgia monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/27b17e6c-82d4-41dd-acd7-5ab9eeaa751b/study-1.png Educational Resources - Fibromyalgia Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Study 1. Psilocybin-assisted therapy in 5 people with fibromyalgia (Aday, 2025) https://doi.org/10.3389/fpain.2025.1527783 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/30980edc-4cca-4473-b0fd-a5019bcfb5d1/study-2.png Educational Resources - Fibromyalgia Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Study 2. Ketamine compared with an active placebo in 24 people with fibromyalgia (Noppers, 2011) https://doi.org/10.1016/j.ejpain.2011.03.008 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/00871d7d-b824-423d-bb47-b092dffe3bc2/study-3.png Educational Resources - Fibromyalgia Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Study 3. Past psychedelic use in 354 people with fibromyalgia (Glynos, 2023) https://doi.org/10.1080/02791072.2021.2022817 https://www.harmreductionadvocate.com/educational-resources/cluster-headache-and-migraine monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bc1230b7-505b-4111-a41d-f7f469c204f5/study-1.png Educational Resources - Cluster Headache and Migraine Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Study 1. Psilocybin in 10 people with migraine (Schindler, 2021) https://doi.org/10.1007/s13311-020-00962-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/be62320a-8781-4aa9-9d2d-081d34d3155c/study-2.png Educational Resources - Cluster Headache and Migraine Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Study 2. Repeat psilocybin pulse in 10 people with cluster headache (Schindler, 2024) https://doi.org/10.1016/j.jns.2024.122993 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c025e598-12b7-436a-bb9f-96f0252d71d2/study-3.png Educational Resources - Cluster Headache and Migraine Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Study 3. Psilocybin and LSD reported by 53 people with cluster headache (Sewell, 2006) https://doi.org/10.1212/01.wnl.0000219761.05466.43 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/53350a8a-3758-46dc-81b3-70613cf439c3/study-4.png Educational Resources - Cluster Headache and Migraine Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Study 4. Psilocybin in 10 people with chronic cluster headache (Madsen, 2024) https://doi.org/10.1111/head.14656 https://www.harmreductionadvocate.com/educational-resources/pain monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b9037ebe-2b8d-4559-be38-1a78e0808fb6/study-1.png Educational Resources - Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Sigtermans MJ, van Hilten JJ, Bauer MCR, et al. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain. 2009;145(3):304-311. https://doi.org/10.1016/j.pain.2009.06.023 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e66c8334-f5c3-425a-9957-7170cd6eadd9/study-2.png Educational Resources - Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Christie D, Yazar-Klosinski B, Nosova E, et al. MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder. Front Psychiatry. 2022;13:939302. https://doi.org/10.3389/fpsyt.2022.939302 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/01cc69e1-d3da-4d64-ad24-3e91a859b90c/study-3.png Educational Resources - Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bonnelle V, Smith WJ, Mason NL, et al. Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey. Br J Pain. 2022;16(6):619-631. https://doi.org/10.1177/20494637221114962 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/25cf5cc8-600f-4d1c-979c-61ffda6a4b91/study-4.png Educational Resources - Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bornemann J, Close JB, Spriggs MJ, et al. Self-Medication for Chronic Pain Using Classic Psychedelics: A Qualitative Investigation to Inform Future Research. Front Psychiatry. 2021;12:735427. https://doi.org/10.3389/fpsyt.2021.735427 https://www.harmreductionadvocate.com/educational-resources/chronic-pain monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/14c2ca58-fc60-43dc-bccb-2a0df9ac2e38/study-1.png Educational Resources - Chronic Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Schindler EAD, Sewell RA, Gottschalk CH, et al. Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. J Neurol Sci. 2024;460:122993. https://doi.org/10.1016/j.jns.2024.122993 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1911e6e2-f1f9-44cd-91f1-a0ee8455ff7e/study-2.png Educational Resources - Chronic Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Schindler EAD, Sewell RA, Gottschalk CH, et al. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics. 2021;18(1):534-543. https://doi.org/10.1007/s13311-020-00962-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1d368ddf-00fc-43e2-a9b6-f9a2376ff9bf/study-3.png Educational Resources - Chronic Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Sewell RA, Halpern JH, Pope HG. Response of cluster headache to psilocybin and LSD. Neurology. 2006;66(12):1920-1922. https://doi.org/10.1212/01.wnl.0000219761.05466.43 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3e086347-8764-47df-a88e-0a111b2362d9/study-4.png Educational Resources - Chronic Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Aday JS, McAfee J, Conroy DA, et al. Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial. Front Pain Res (Lausanne). 2025;6:1527783. https://doi.org/10.3389/fpain.2025.1527783 https://www.harmreductionadvocate.com/educational-resources/opioid-use-disorder monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/56d8a5dd-d21a-4b77-8a89-a291ee8f199d/study-1.png Educational Resources - Opioid Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Krupitsky E, Burakov A, Romanova T, et al. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat. 2002;23(4):273-283. https://doi.org/10.1016/s0740-5472(02)00275-1 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c542e288-da05-4a5b-8460-8efe64c1c793/study-2.png Educational Resources - Opioid Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Krupitsky EM, Burakov AM, Dunaevsky IV, et al. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs. 2007;39(1):13-19. https://doi.org/10.1080/02791072.2007.10399860 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/785cb5f7-885b-44d5-a722-93164579a63b/study-3.png Educational Resources - Opioid Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36. https://doi.org/10.1080/00952990.2017.1320802 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7ce610b6-f2c5-4337-8c96-bcc4d5ebd29c/study-4.png Educational Resources - Opioid Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Argento E, Socias ME, Hayashi K, et al. Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting. Int J Drug Policy. 2022;100:103518. https://doi.org/10.1016/j.drugpo.2021.103518 https://www.harmreductionadvocate.com/educational-resources/tobacco-and-nicotine-use-disorder monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7f8544ab-91e7-4672-9064-d007703ac876/study-1.png Educational Resources - Tobacco and Nicotine Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Johnson MW, Naudé GP, Hendricks PS, et al. Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial. JAMA Netw Open. 2026;9(3):e260972. https://doi.org/10.1001/jamanetworkopen.2026.0972 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d2422a33-ff43-40cb-a66d-ca9fb90aa801/study-2.png Educational Resources - Tobacco and Nicotine Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Johnson MW, Garcia-Romeu A, Cosimano MP, et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983-992. https://doi.org/10.1177/0269881114548296 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2102ea65-fd37-4475-a2fd-ec32734d3375/study-3.png Educational Resources - Tobacco and Nicotine Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Johnson MW, Garcia-Romeu A, Johnson PS, et al. An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. J Psychopharmacol. 2017;31(7):841-850. https://doi.org/10.1177/0269881116684335 https://www.harmreductionadvocate.com/educational-resources/schizophrenia monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/66fe4569-7842-4076-a3f9-d76b430cab41/study-1.png Educational Resources - Schizophrenia Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Sabé M, Sulstarova A, Glangetas A, et al. Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies. Mol Psychiatry. 2025;30(3):1223-1255. https://doi.org/10.1038/s41380-024-02800-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3d0e1f07-a4d8-49b8-836c-a4cec8830aa0/study-2.png Educational Resources - Schizophrenia Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Steinle JT, Shankar S, Siegel JS, et al. Hallucinogen-Psychosis Associations Are Confounded by Baseline Psychiatric History. J Clin Psychiatry. 2026;87(3):25m16034. https://doi.org/10.4088/jcp.25m16034 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/323ea6a9-5285-4766-8497-47bf4b2c1ad4/study-3.png Educational Resources - Schizophrenia Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Brar PS, Price RB, Ross S, et al. The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential. J Psychopharmacol. 2026;40(7):1037-1053. https://doi.org/10.1177/02698811261456191 https://www.harmreductionadvocate.com/educational-resources/eating-disorders monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4acdee9a-e01f-4707-a4de-51253e5a2cc0/study-1.png Educational Resources - Eating Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Brewerton TD, Wang JB, Lafrance A, et al. MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD. J Psychiatr Res. 2022;149:128-135. https://doi.org/10.1016/j.jpsychires.2022.03.008 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/543f5a72-3290-4f82-8654-1ca92934e3f5/study-2.png Educational Resources - Eating Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Douglass HM, Spriggs MJ, Godfrey K, et al. Psilocybin therapy for adult females with anorexia nervosa: pilot study. Br J Psychiatry. Published online July 8, 2026:1-9. https://doi.org/10.1192/bjp.2026.10687 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0f1f9058-6935-4dea-a6af-655b04fb2f43/study-3.png Educational Resources - Eating Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Peck SK, Shao S, Gruen T, et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med. 2023;29(8):1947-1953. https://doi.org/10.1038/s41591-023-02455-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/612a7bc7-b67d-4771-bb41-835a293d4532/study-4.png Educational Resources - Eating Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Dallery J, Miller JL, Boissoneault J, et al. An open-label pilot study of psilocybin-assisted therapy for binge eating disorder. J Eat Disord. 2026;14(1):41. https://doi.org/10.1186/s40337-025-01508-3 https://www.harmreductionadvocate.com/educational-resources/personality-disorders monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1b5982b7-b42d-4078-9230-351b19fc3185/study-1.png Educational Resources - Personality Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Fineberg SK, Choi EY, Shapiro-Thompson R, et al. A pilot randomized controlled trial of ketamine in Borderline Personality Disorder. Neuropsychopharmacology. 2023;48(7):991-999. https://doi.org/10.1038/s41386-023-01540-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/851b3bd2-8ef6-47d7-af2a-ece7f8496088/study-2.png Educational Resources - Personality Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Grant JE, Boutouis S, O'Brien M, et al. An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder. Clin Neuropharmacol. 2026;49(4):163-169. https://doi.org/10.1097/wnf.0000000000000683 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/55e62796-7648-4330-8295-c5a7bf7a86ca/study-3.png Educational Resources - Personality Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Raffone F, Mazzoni F, De Ciechi A, et al. Esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A real-world longitudinal study of suicidal ideation and self-harm. Asian J Psychiatr. 2026;120:104983. https://doi.org/10.1016/j.ajp.2026.104983 https://www.harmreductionadvocate.com/educational-resources/suicidality monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/782b450a-86a4-417d-a9ee-9dd339bd3c15/study-1.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. 2022;387(18):1637-1648. https://doi.org/10.1056/nejmoa2206443 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6cca089a-c5df-4d79-88f0-1606084474db/study-2.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Zeifman RJ, Palhano-Fontes F, Hallak J, Arcoverde E, Maia-Oliveira JP, Araujo DB. The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial. Front Pharmacol. 2019;10:1325. https://doi.org/10.3389/fphar.2019.01325 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/dc186ba5-9ee5-4096-90d7-57d8354076b9/study-3.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hinkle JT, Graziosi M, Nayak SM, Yaden DB. Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2024;81(12):1225-1235. https://doi.org/10.1001/jamapsychiatry.2024.2546 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f701c705-554d-48b2-8a55-39f696969ce7/study-4.png Educational Resources - Suicidality Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Meshkat S, Malik T, Zeifman R, et al. Psychedelics and Suicide-Related Outcomes: A Systematic Review. J Clin Med. 2025;14(5):1416. https://doi.org/10.3390/jcm14051416 https://www.harmreductionadvocate.com/educational-resources/obsessive-compulsive-disorder monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a0577280-818d-42c7-a0c3-b2b7a4fec3fa/study-1.png Educational Resources - Obsessive-Compulsive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Moreno FA, Allen KE, Wiegand CB, et al. A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder. J Psychopharmacol. 2026;40(5):837-849. https://doi.org/10.1177/02698811261424214 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/cdc4fc3a-5581-4e62-8081-2fe51c5313da/study-2.png Educational Resources - Obsessive-Compulsive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Pellegrini L, Fineberg NA, O'Connor S, et al. Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study. Compr Psychiatry. 2025;142:152619. https://doi.org/10.1016/j.comppsych.2025.152619 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0aa95b5d-a46c-45c9-aa46-50ff0c63b68b/study-3.png Educational Resources - Obsessive-Compulsive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Beaglehole B, Glue P, Neehoff S, et al. Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled crossover study. J Psychopharmacol. 2025;39(1):23-28. https://doi.org/10.1177/02698811241301215 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ecb69609-5987-4bb8-bd39-8b7f09c07cb8/study-4.png Educational Resources - Obsessive-Compulsive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735-1740. https://doi.org/10.4088/jcp.v67n1110 https://www.harmreductionadvocate.com/educational-resources/adhd monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f07d6285-d0e1-4637-b173-92d41dc0c19e/study-1.png Educational Resources - ADHD Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mueller L, Santos de Jesus J, Schmid Y, et al. Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(6):555-562. https://doi.org/10.1001/jamapsychiatry.2025.0044 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/68618571-670c-49e4-b67c-efe3d5407cef/study-2.png Educational Resources - ADHD Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Haijen-Bongers ECHM, Hurks PPM, Schepers J, et al. Effects of repeated low-dose LSD on neuropsychological functioning in adults with ADHD: a randomized placebo-controlled study. Psychopharmacology (Berl). 2026. https://doi.org/10.1007/s00213-026-07107-7 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a417f264-3de0-4f5f-bf64-dbc9b7df76dd/study-3.png Educational Resources - ADHD Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Haijen ECHM, Hurks PPM, Kuypers KPC. Effects of psychedelic microdosing versus conventional ADHD medication use on emotion regulation, empathy, and ADHD symptoms in adults with severe ADHD symptoms: A naturalistic prospective comparison study. Eur Psychiatry. 2024;67(1):e18. https://doi.org/10.1192/j.eurpsy.2024.8 https://www.harmreductionadvocate.com/educational-resources/autism monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/329d9abb-8175-409e-9e30-15fc53144285/study-1.png Educational Resources - Autism Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Danforth AL, Grob CS, Struble C, et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology (Berl). 2018;235(11):3137-3148. https://doi.org/10.1007/s00213-018-5010-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/03789fb4-af3b-4d59-af6d-96bf22c7ce3b/study-2.png Educational Resources - Autism Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Stroud J, Rice C, Orsini A, et al. Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey. Psychopharmacology (Berl). 2025;242(2):373-387. https://doi.org/10.1007/s00213-024-06685-8 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7ed53eda-bab1-4e6f-b266-c1d00921c6a6/study-3.png Educational Resources - Autism Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Afsharnia S, Liang V, Lunsky Y, et al. Knowledge, perceptions, and use of psychedelics for mental health among autistic adults: An online survey. PLOS Ment Health. 2025;2(12):e0000514. https://doi.org/10.1371/journal.pmen.0000514 https://www.harmreductionadvocate.com/educational-resources/adolescents monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fb3ca66d-143d-4ee6-afc7-6aa9c0a03163/study-1.png Educational Resources - Adolescents Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Pardossi S, Fagiolini A, Scheggi S, et al. A Systematic Review on Ketamine and Esketamine for Treatment-Resistant Depression and Suicidality in Adolescents: A New Hope? Children (Basel). 2024;11(7):801. https://doi.org/10.3390/children11070801 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ed5e5a07-10f7-43ad-9bba-85031114a09c/study-2.png Educational Resources - Adolescents Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Simonsson O, Mosing MA, Osika W, et al. Adolescent Psychedelic Use and Psychotic or Manic Symptoms. JAMA Psychiatry. 2024;81(6):579-585. https://doi.org/10.1001/jamapsychiatry.2024.0047 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a5d8a10e-e83d-4a9a-a221-1baaf62467a6/study-3.png Educational Resources - Adolescents Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Cullen KR, Amatya P, Roback MG, et al. Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study. J Child Adolesc Psychopharmacol. 2018;28(7):437-444. https://doi.org/10.1089/cap.2018.0030 https://www.harmreductionadvocate.com/educational-resources/acute-pain monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8b338e65-8333-4045-9519-7276c59a6137/study-1.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Smyth MA, Noordali H, Starr K, et al. Paramedic analgesia comparing ketamine and morphine in trauma (PACKMaN): a randomised, double-blind, phase 3 trial. Lancet Reg Health Eur. 2025;53:101265. https://doi.org/10.1016/j.lanepe.2025.101265 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/caf3c8b0-8d1b-4679-9e0e-dfe0ff55346f/study-2.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Motov S, Rockoff B, Cohen V, et al. Intravenous Subdissociative-Dose Ketamine Versus Morphine for Analgesia in the Emergency Department: A Randomized Controlled Trial. Ann Emerg Med. 2015;66(3):222-229.e1. https://doi.org/10.1016/j.annemergmed.2015.03.004 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/31920bee-7853-4dc0-aecb-888b47cf5a30/study-3.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ramaekers JG, Hutten N, Mason NL, et al. A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. J Psychopharmacol. 2021;35(4):398-405. https://doi.org/10.1177/0269881120940937 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2e819198-1c49-43e0-8740-d29ae42a7f0f/study-4.png Educational Resources - Acute Pain Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Beaudoin FL, Lin C, Guan W, Merchant RC. Low-dose ketamine improves pain relief in patients receiving intravenous opioids for acute pain in the emergency department: results of a randomized, double-blind, clinical trial. Acad Emerg Med. 2014;21(11):1193-1202. https://doi.org/10.1111/acem.12510 https://www.harmreductionadvocate.com/educational-resources/alcohol-use-disorder monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fe0f9633-901c-46b2-a7bf-1b2c49933aed/study-1.png Educational Resources - Alcohol Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022;79(10):953-962. https://doi.org/10.1001/jamapsychiatry.2022.2096 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/220ba00d-b5e4-4cd5-b350-c9fc69a102d7/study-2.png Educational Resources - Alcohol Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Florineth GA, Boeker AL, Bracht T, et al. Efficacy and safety of psilocybin-assisted therapy for alcohol use disorder: a systematic review and meta-analysis. J Psychopharmacol. Published online October 8, 2026. https://doi.org/10.1177/02698811261490221 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/168c503c-9873-413e-aa27-52716dbc6555/study-3.png Educational Resources - Alcohol Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Luquiens A, Belahda D, Graux C, et al. Psilocybin in alcohol use disorder and comorbid depressive symptoms: results from a feasibility randomized clinical trial. Addiction. Published online July 24, 2025. https://doi.org/10.1111/add.70152 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a7aeb29c-081e-4476-b518-e564e6c514db/study-4.png Educational Resources - Alcohol Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Krebs TS, Johansen PØ. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. 2012;26(7):994-1002. https://doi.org/10.1177/0269881112439253 https://www.harmreductionadvocate.com/educational-resources/borderline-personality-disorder monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4f338baa-c0d2-4cf6-9c87-42e51eaa214e/study-1.png Educational Resources - Borderline Personality Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Fineberg SK, Choi EY, Shapiro-Thompson R, et al. A pilot randomized controlled trial of ketamine in Borderline Personality Disorder. Neuropsychopharmacology. 2023;48(7):991-999. https://doi.org/10.1038/s41386-023-01540-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4606e0c4-698c-4eb3-8051-1bb2b3fe46b1/study-2.png Educational Resources - Borderline Personality Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Grant JE, Boutouis S, O'Brien M, et al. An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder. Clin Neuropharmacol. 2026;49(4):163-169. https://doi.org/10.1097/wnf.0000000000000683 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/676efe2e-c773-4662-ab87-4e8a5e050411/study-3.png Educational Resources - Borderline Personality Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Danayan K, Chisamore N, Rodrigues NB, et al. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder. Psychiatry Res. 2023;323:115133. https://doi.org/10.1016/j.psychres.2023.115133 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/906d9b72-06d4-4c32-a8d3-a32713c64fd7/study-4.png Educational Resources - Borderline Personality Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Raffone F, Mazzoni F, De Ciechi A, et al. Esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A real-world longitudinal study of suicidal ideation and self-harm. Asian J Psychiatr. 2026;120:104983. https://doi.org/10.1016/j.ajp.2026.104983 https://www.harmreductionadvocate.com/educational-resources/anxiety-disorders monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1204c6c2-d11a-44c3-94be-8b938e83c396/study-1.png Educational Resources - Anxiety Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Robison R, Barrow R, Conant C, et al. Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial. JAMA. 2025;334(15):1358-1372. https://doi.org/10.1001/jama.2025.13481 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0b7b1823-fc1f-42a3-94d3-bb951743fbd9/study-2.png Educational Resources - Anxiety Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Holze F, Gasser P, Müller F, et al. Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Biol Psychiatry. 2023;93(3):215-223. https://doi.org/10.1016/j.biopsych.2022.08.025 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/18551cf5-256d-40d7-ba2d-8a82f26ce5e5/study-3.png Educational Resources - Anxiety Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Danforth AL, Grob CS, Struble C, et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology (Berl). 2018;235(11):3137-3148. https://doi.org/10.1007/s00213-018-5010-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/03735dc9-3dbb-4a66-93c1-c72f497a217c/study-4.png Educational Resources - Anxiety Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Dos Santos RG, Osório FL, Rocha JM, et al. Ayahuasca Improves Self-perception of Speech Performance in Subjects With Social Anxiety Disorder: A Pilot, Proof-of-Concept, Randomized, Placebo-Controlled Trial. J Clin Psychopharmacol. 2021;41(5):540-550. https://doi.org/10.1097/jcp.0000000000001428 https://www.harmreductionadvocate.com/educational-resources/bipolar-disorder monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7534a769-6f2a-4d07-80fc-8203264ab7bc/study-1.png Educational Resources - Bipolar Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Eskinazi M, Nasserdine R, Cusin RM, et al. Psychedelic-induced hypomania and mania: a systematic review and meta-analysis. Mol Psychiatry. 2026;31(10):5749-5763. https://doi.org/10.1038/s41380-026-03657-6 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/68ed0791-66e2-4551-afe2-63cf1bb6fcb1/study-2.png Educational Resources - Bipolar Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Downey AE, Szigeti B, Bradley ER, et al. An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression. J Clin Psychiatry. 2026;87(4):25m16227. https://doi.org/10.4088/jcp.25m16227 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/55bc0396-1cb9-41d3-98c4-00739f06c801/study-3.png Educational Resources - Bipolar Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Aaronson ST, van der Vaart A, Miller T, et al. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial. JAMA Psychiatry. 2024;81(6):555-562. https://doi.org/10.1001/jamapsychiatry.2023.4685 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/913c128b-ddfa-412c-b114-eeff12d1e8bc/study-4.png Educational Resources - Bipolar Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Morton E, Sakai K, Ashtari A, Pleet M, Michalak EE, Woolley J. Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption. J Psychopharmacol. 2023;37(1):49-60. https://doi.org/10.1177/02698811221131997 https://www.harmreductionadvocate.com/educational-resources/treatment-resistant-depression monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/fa36adda-ff5d-4118-894c-36b5f304b461/study-1.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. 2022;387(18):1637-1648. https://doi.org/10.1056/nejmoa2206443 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2b277ec7-120a-446e-9bdf-e7d47791c9ec/study-2.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Rosenblat JD, Meshkat S, Doyle Z, et al. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med. 2024;5(3):190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c2c29cc9-8b5a-4332-9e4e-45093aee05b3/study-3.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Rucker JJ, Mantingh T, Kerr-Gaffney J, et al. Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial. Nat Med. 2026;32(9):3430-3437. https://doi.org/10.1038/s41591-026-04541-0 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/eecba2d2-602c-4caf-a8d0-694c812f1fe2/study-4.png Educational Resources - Treatment-Resistant Depression Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655-663. https://doi.org/10.1017/s0033291718001356 https://www.harmreductionadvocate.com/educational-resources/major-depressive-disorder monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/87112676-3999-4942-9a76-d9483c92cc3f/illustration-2.png Educational Resources - Major Depressive Disorder https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/57e2d1ef-6369-4876-9da8-c13fd940c416/study-1.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Raison CL, Sanacora G, Woolley J, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. 2023;330(9):843-853. https://doi.org/10.1001/jama.2023.14530 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/72d0bec1-183e-4475-89a3-944cf9a4a925/study-2.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021;384(15):1402-1411. https://doi.org/10.1056/nejmoa2032994 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6ccffa2d-8034-4a12-90a1-622c5d5fd1bc/study-3.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Yngwe H, Plavén-Sigray P, Ekman CJ, et al. Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial. JAMA Netw Open. 2026;9(5):e2612589. https://doi.org/10.1001/jamanetworkopen.2026.12589 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c2ad2948-7f57-4f2b-836a-7cf1c4166a32/study-4.png Educational Resources - Major Depressive Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Erritzoe D, Barba T, Benway T, et al. A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial. Nat Med. 2026;32(2):591-598. https://doi.org/10.1038/s41591-025-04154-z https://www.harmreductionadvocate.com/educational-resources/depressive-disorders monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6f5524eb-b610-4a1e-91f7-4ddabc96d2b1/illustration-1.png Educational Resources - Depressive Disorders https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8f359d03-3cb2-465b-9b25-16721a0ed689/study-1.png Educational Resources - Depressive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Back AL, Freeman-Young TK, Morgan L, et al. Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial. JAMA Netw Open. 2024;7(12):e2449026. https://doi.org/10.1001/jamanetworkopen.2024.49026 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c99fde33-f55b-41b8-9424-afbf6208ff7f/study-2.png Educational Resources - Depressive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Lewis BR, Hendrick J, Byrne K, Odette M, Wu C, Garland EL. Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PLoS Med. 2025;22(9):e1004519. https://doi.org/10.1371/journal.pmed.1004519 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0ccb5a9d-3ec2-43aa-8f73-d0b8c2064098/study-3.png Educational Resources - Depressive Disorders Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hsu TW, Tsai CK, Kao YC, et al. Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis. BMJ. 2024;386:e078607. https://doi.org/10.1136/bmj-2023-078607 https://www.harmreductionadvocate.com/educational-resources/event-one-8katj-py3ae monthly 0.5 2026-10-27 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8e0d647a-72e7-4faa-9450-8df4b760f152/_82e22bb4-280b-4ea8-8d98-528a4532c8f1.jpg Educational Resources - End of Life Distress - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/713f91a0-6595-4dcd-8d0f-0f7eba2d8551/griffiths-2016-title-and-abstract-highlighted.png Educational Resources - End of Life Distress Screenshot of the article as published in Journal of Psychopharmacology (2016), via PubMed Central. CC BY 3.0. Yellow highlighting added. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8231a291-0b6d-4c65-a674-174e4ce56424/ross-2016-title-and-abstract-part-1-highlighted.png Educational Resources - End of Life Distress Screenshot of the article as published in Journal of Psychopharmacology (2016), via PubMed Central, part 1 of 2. CC BY 3.0. Yellow highlighting added. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3f4f8943-4b41-4191-ab35-3d78d3860e3a/ross-2016-abstract-part-2-highlighted.png Educational Resources - End of Life Distress Screenshot of the article as published in Journal of Psychopharmacology (2016), via PubMed Central, part 2 of 2. CC BY 3.0. Yellow highlighting added. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/98a961cc-483d-49c3-8820-22f0ec2b0b17/ross-2025-title-block-clean.png Educational Resources - End of Life Distress Screenshot of the article’s title block as published in General Hospital Psychiatry (2025), via PubMed. The abstract is at the DOI link above. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d4e66836-959e-4bed-a5c8-ae2420e985ab/gasser-2014-title-and-abstract-clean.png Educational Resources - End of Life Distress Screenshot of the article as published in The Journal of Nervous and Mental Disease (2014), via PubMed Central. CC BY-NC-ND 3.0. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9a401db6-11b2-449f-a084-70e79f604d6a/Screen+Shot+2024-01-21+at+9.20.36+PM.png Educational Resources - End of Life Distress - Make it stand out Psilocybin Benefits in Cancer Sustained Nearly 5 Years Later. Medscape. (2020, January 28). https://www.medscape.com/viewarticle/924368?form=fpf https://www.harmreductionadvocate.com/educational-resources/event-one-8katj-tzy3n monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e42bc86b-9e73-49a9-b755-5d07fbfad6fc/_fc963efa-cee6-4d4f-9100-8751dbbfc64a.jpg Educational Resources - Physical Well Being - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/abfe5c23-cc70-4c17-b865-306387f3de05/study-1.png Educational Resources - Physical Well Being Excerpt of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Simonsson O, Sexton JD, Hendricks PS. Associations between lifetime classic psychedelic use and markers of physical health. J Psychopharmacol. 2021;35(4):447-452. https://doi.org/10.1177/0269881121996863 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/460fe1ee-fcf3-4466-a24d-d85a71e6c831/study-27.png Educational Resources - Physical Well Being Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197. https://doi.org/10.1177/0269881116675513 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/e1fc3e7b-d379-49a8-9478-d8449256dead/study-3.png Educational Resources - Physical Well Being Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Wen Y, Tang L, Duan W, et al. Targeting peripheral 5-HT2AR enhances antitumor immunity in colorectal cancer. Cell. 2026;189(18):5688-5705.e13. https://doi.org/10.1016/j.cell.2026.07.028 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1452ab9c-0383-4571-82b9-0eac561b7b17/study-4.png Educational Resources - Physical Well Being Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Heles M, Pasvolsky L, Sathishkumar H, et al. Psilocybin prevents chemotherapy-induced peripheral neuropathy through mitochondrial trafficking preservation. Science. 2026;393(6815):eaec6116. https://doi.org/10.1126/science.aec6116 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2d69e625-e532-407a-8df0-470e10b53504/study-5.png Educational Resources - Physical Well Being Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Tourino MC, de Oliveira EM, Bellé LP, et al. Tryptamine and dimethyltryptamine inhibit indoleamine 2,3 dioxygenase and increase the tumor-reactive effect of peripheral blood mononuclear cells. Cell Biochem Funct. 2013;31(5):361-364. https://doi.org/10.1002/cbf.2980 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/88f899f5-79d4-414a-8c26-e7d91ba52ed8/study-6.png Educational Resources - Physical Well Being Excerpt of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Frecska E, Bokor P, Winkelman M. The therapeutic potentials of ayahuasca: possible effects against various diseases of civilization. Front Pharmacol. 2016;7:35. https://doi.org/10.3389/fphar.2016.00035 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/39789e99-82c5-44a4-8972-766ce1f435ed/study-7.png Educational Resources - Physical Well Being Excerpt of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Szabo A. Psychedelics and immunomodulation: novel approaches and therapeutic opportunities. Front Immunol. 2015;6:358. https://doi.org/10.3389/fimmu.2015.00358 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7a2f4d18-a6cb-4536-b79e-7745fe974afe/study-8.png Educational Resources - Physical Well Being Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: van Waarde A, Rybczynska AA, Ramakrishnan NK, Ishiwata K, Elsinga PH, Dierckx RA. Potential applications for sigma receptor ligands in cancer diagnosis and therapy. Biochim Biophys Acta. 2015;1848(10 Pt B):2703-2714. https://doi.org/10.1016/j.bbamem.2014.08.022 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f05a976f-8a9e-47aa-a79f-50fa27579aec/Screen+Shot+2024-01-21+at+7.19.49+PM.png Educational Resources - Physical Well Being - Make it stand out Schenberg EE. Ayahuasca and cancer treatment. SAGE Open Med. 2013;1:2050312113508389. https://doi.org/10.1177/2050312113508389 · Screenshot of the published record (PubMed). https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ab880d04-66d0-480e-9d03-557dc7315877/study-9.png Educational Resources - Physical Well Being Page of the U.S. National Cancer Institute (public domain), key sentence highlighted in yellow. Source: PDQ Integrative, Alternative, and Complementary Therapies Editorial Board. Cannabis and Cannabinoids (PDQ®)–Health Professional Version. National Cancer Institute. Updated May 13, 2025. Accessed October 27, 2026. https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b09c19db-3e27-4212-8fca-f6f2627f8b60/study-11.png Educational Resources - Physical Well Being Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Hinz B, Ramer R. Cannabinoids as anticancer drugs: current status of preclinical research. Br J Cancer. 2022;127(1):1-13. https://doi.org/10.1038/s41416-022-01727-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/48595a40-3aaa-41c2-9ce3-9e70f7c7f7df/study-12.png Educational Resources - Physical Well Being Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Torres S, Lorente M, Rodríguez-Fornés F, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther. 2011;10(1):90-103. https://doi.org/10.1158/1535-7163.MCT-10-0688 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/51312353-1d9c-45eb-ba78-a7c8ed85fdd4/study-13.png Educational Resources - Physical Well Being Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. https://doi.org/10.1038/sj.bjc.6603236 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1f96d1d6-55f8-4675-8cc1-330905ee8054/study-14.png Educational Resources - Physical Well Being Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Twelves C, Sabel M, Checketts D, et al. A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. Br J Cancer. 2021;124(8):1379-1387. https://doi.org/10.1038/s41416-021-01259-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/af69aa9e-807c-440c-9f2e-b871f9e7fe31/study-17.png Educational Resources - Physical Well Being Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Braun IM, Bohlke K, Abrams DI, et al. Cannabis and cannabinoids in adults with cancer: ASCO guideline. J Clin Oncol. 2024;42(13):1575-1593. https://doi.org/10.1200/JCO.23.02596 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/26f6d299-b660-4a96-96e9-89d7a404baaf/study-21.png Educational Resources - Physical Well Being Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Waissengrin B, Leshem Y, Taya M, et al. The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: a sigh of relief? Eur J Cancer. 2023;180:52-61. https://doi.org/10.1016/j.ejca.2022.11.022 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/63f3be53-4577-4bf9-96ba-b3c53d17549b/study-22.png Educational Resources - Physical Well Being Excerpt of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Simonsson O, Osika W, Carhart-Harris R, Hendricks PS. Associations between lifetime classic psychedelic use and cardiometabolic diseases. Sci Rep. 2021;11(1):14427. https://doi.org/10.1038/s41598-021-93787-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/362d4972-1030-4560-8e38-b1a0cb3fc471/study-23.png Educational Resources - Physical Well Being Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Haupt MJ, Carra S, Boehnke KF, Aday JS. Preliminary effects of ayahuasca on mental and physical health: A systematic review of prospective studies. Prog Neuropsychopharmacol Biol Psychiatry. 2026;145:111634. https://doi.org/10.1016/j.pnpbp.2026.111634 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7ed2658a-c2a9-4b4e-9896-f006b4a726d5/study-28.png Educational Resources - Physical Well Being Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983-992. https://doi.org/10.1177/0269881114548296 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/64c9f6b4-6f65-4aa9-9f5f-1e80b004ea88/study-25.png Educational Resources - Physical Well Being Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Swieczkowski D, Kwaśny A, Cubała WJ. Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and Major Depressive Disorder (MDD) patients: A systematic review of early-phase clinical trials. Prog Neuropsychopharmacol Biol Psychiatry. 2025;140:111419. https://doi.org/10.1016/j.pnpbp.2025.111419 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7d72bcc1-2d5e-461c-a7aa-a046148e6a74/study-26.png Educational Resources - Physical Well Being Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Yerubandi A, Thomas JE, Bhuiya NMMA, et al. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024;7(4):e245960. https://doi.org/10.1001/jamanetworkopen.2024.5960 https://www.harmreductionadvocate.com/educational-resources/event-one-8katj-s4scw monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0e23b0e1-d9a8-4e96-a22b-ea1ebd078ba1/_9e2f3f2b-80c0-4bcb-bf84-2ea581dcd3ae.jpg Educational Resources - Wellness of the Planet - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/37b78d61-0a62-4d46-aa4d-f992306a6549/_67cc4818-95e5-4235-8fd6-8806e71c15c0.jpg Educational Resources - Wellness of the Planet - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/56172a4f-0d72-46f6-b147-bea8641d7d1b/Screen+Shot+2024-01-28+at+10.56.38+PM.png Educational Resources - Wellness of the Planet - Make it stand out Nilsson M, Stålhammar S. Psychedelics and inner dimensions of sustainability: a literature review. Eur J Ecopsychol. 2024;9:4-47. https://ecopsychology-journal.eu/v9/EJEv9NilssonandSt%C3%A5lhammar.pdf · Screenshot of the first page of the published review (European Journal of Ecopsychology). https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/651acd61-b7df-47ea-ae9a-981f1b261cc5/study-1.png Educational Resources - Wellness of the Planet Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Rich R, Laird K, Siddarth P, et al. A Nature-Themed Video Intervention Increases Nature Relatedness in Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder. Psychedelic Med (New Rochelle). 2026;4(3):199-208. https://doi.org/10.1177/28314425251387655 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a049c37f-0c77-419c-b148-d6e07ca2caf0/study-2.png Educational Resources - Wellness of the Planet Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Forstmann M, Sagioglou C. Psychedelics and connectedness to natural and social worlds: An examination of the evidence and a proposed conceptual framework. Curr Opin Psychol. 2025;62:101992. https://doi.org/10.1016/j.copsyc.2025.101992 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bfa312a1-6d9a-4cfe-a074-4bcb887e456f/study-3.png Educational Resources - Wellness of the Planet Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Lyons T, Carhart-Harris RL. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. J Psychopharmacol. 2018;32(7):811-819. https://doi.org/10.1177/0269881117748902 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/234d4c3c-ac8b-4b8a-bb69-0cdb4078a5c5/study-4.png Educational Resources - Wellness of the Planet Quotation from the abstract of the published study (text from the publisher’s page, Scientific Reports), highlighted in yellow. Source: Teixeira PJ, Cherniak AD, Forstmann M. Lifetime classic psychedelics use is associated with positive environmental attitudes and adopting a vegetarian diet. Sci Rep. Published online September 11, 2026. https://doi.org/10.1038/s41598-026-71275-x https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c15b87de-8405-44c5-af48-1d92dea7b47d/study-5.png Educational Resources - Wellness of the Planet Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Forstmann M, Sagioglou C. Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness. J Psychopharmacol. 2017;31(8):975-988. https://doi.org/10.1177/0269881117714049 https://www.harmreductionadvocate.com/educational-resources/event-one-8katj-bst5y monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5920747b-1c5e-4757-8bf3-35fedf661366/_b0d769d5-8d51-412e-b142-acd3b63e3eac.jpg Educational Resources - PTSD - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ad008346-aa43-4ffb-84e3-3ac3cc3aa00d/study-A.png Educational Resources - PTSD Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Poddar A, Raggio M, Concato J. Decisions on non-oncology breakthrough therapy designation requests in 2017-2019. Ther Innov Regul Sci. 2024;58(1):214-221. https://doi.org/10.1007/s43441-023-00589-z https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/917efffc-79f7-40e5-a802-5a194c9e9478/study-B.png Educational Resources - PTSD Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Herink MC, Johnston K, Breninger K, Wu E, Irwin AN. Pharmacists’ knowledge and perceptions of FDA approval standards and the breakthrough therapy designation. Pharmacy (Basel). 2022;10(5):126. https://doi.org/10.3390/pharmacy10050126 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f083428d-079a-4479-b5c7-b3778ae746c1/study-C.png Educational Resources - PTSD Quotation from the journal's retraction notice, highlighted in yellow. Source: Jerome L, Feduccia AA, Wang JB, et al. Retraction Note: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl). 2024;241(11):2407. https://doi.org/10.1007/s00213-024-06665-y https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c246fb76-934d-4ebc-ade0-66afdc669a22/study-D.png Educational Resources - PTSD Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025-1033. https://doi.org/10.1038/s41591-021-01336-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/cf01af8a-3be1-4870-acd7-0de937b15317/study-E.png Educational Resources - PTSD Abstract of the published study (text from Europe PMC), key sentence quoted in the text above. Source: Davis AK, Averill LA, Sepeda ND, Barsuglia JP, Amoroso T. Psychedelic treatment for trauma-related psychological and cognitive impairment among US Special Operations Forces veterans. Chronic Stress (Thousand Oaks). 2020;4:2470547020939564. https://doi.org/10.1177/2470547020939564 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9ad6d76e-7903-4668-b242-c6fc6fdc3716/study-F.png Educational Resources - PTSD Text of the published study (from Europe PMC), key sentence highlighted in yellow. Source: Kéri S. Psychedelic safety and clinical outcomes across exposure patterns: a structured narrative review. Life (Basel). 2026;16(8):1338. https://doi.org/10.3390/life16081338 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f587524d-1ea1-46c7-a721-17b7557fa544/study-1.png Educational Resources - PTSD Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Thomas JE, Dellarole A, Caballero J. Efficacy and risks of psychedelics in the treatment of posttraumatic stress disorder: A systematic review. Am J Health Syst Pharm. 2026;83(16):822-834. https://doi.org/10.1093/ajhp/zxag062 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7f91b129-0d62-474c-88f9-1c773287910c/study-2.png Educational Resources - PTSD Text of the published study (from Europe PMC), key sentence highlighted in yellow. Source: Sze Jing Yong A, Bratuskins S, Sultani MS, Blakeley B, Davey CG, Bell JS. Safety and efficacy of methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in post-traumatic stress disorder: An overview of systematic reviews and meta-analyses. Aust N Z J Psychiatry. 2025;59(4):339-360. https://doi.org/10.1177/00048674251315642 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7493b6b8-5305-409a-85ad-0b7203760ac2/study-3.png Educational Resources - PTSD Text of the published study (from Europe PMC), key sentence highlighted in yellow. Source: Mitchell JM, Ot'alora G M, van der Kolk B, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29(10):2473-2480. https://doi.org/10.1038/s41591-023-02565-4 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/52c4457f-3d8e-4142-9f3f-615c8000b63c/study-4.png Educational Resources - PTSD Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Abdallah CG, Roache JD, Gueorguieva R, et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology. 2022;47(8):1574-1581. https://doi.org/10.1038/s41386-022-01266-9 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8004177c-6ef9-4b57-afe8-225be29c1c3a/study-5.png Educational Resources - PTSD Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Sevchik BL, Singleton SP, Lahey A, et al. A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD. Neuropsychopharmacology. Published online October 11, 2026. https://doi.org/10.1038/s41386-026-02575-z https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6a0b36fc-eccc-435b-b32c-63b4b18fca52/study-6.png Educational Resources - PTSD Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Jones A, Warner-Schmidt J, Kwak H, et al. Efficacy and safety of the neuroplastogen TSND-201 for the treatment of PTSD: a randomized clinical trial. JAMA Psychiatry. 2026;83(5):469-477. https://doi.org/10.1001/jamapsychiatry.2025.4625 https://www.harmreductionadvocate.com/educational-resources/event-one-8katj-69lhb monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/751eede4-a88a-4d1f-95b6-3c833c29c2cc/_cdf08c3c-2b17-447f-b98c-258876ccc0a7.jpg Educational Resources - Wellness of the ‘Well’ - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2dc02aa8-93b9-4244-ad1f-28ced32ce21f/Screen+Shot+2024-01-22+at+7.11.46+PM.png Educational Resources - Wellness of the ‘Well’ - Make it stand out “Magic mushrooms have been linked to lower crime rates” Foley KE. Psychedelics may make people less likely to commit violent crimes. Quartz. Published October 19, 2017. https://qz.com/1105554/psychedelics-may-make-people-less-likely-to-commit-violent-crimes · Screenshot of the Quartz article. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/c59f36a6-6568-467e-9751-b7a4fbb65ed9/study-1.png Educational Resources - Wellness of the ‘Well’ Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Klučková T, Nikolič M, Tylš F, et al. The phenomenology of psilocybin's experience mediates subsequent persistent psychological effects independently of sex, previous experience, or setting. Pharmacol Rep. 2025;77(4):1024-1039. https://doi.org/10.1007/s43440-025-00742-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f3cd6f01-a5cf-44a7-9b8b-4b9ee0684b6c/study-2.png Educational Resources - Wellness of the ‘Well’ Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Schmid Y, Liechti ME. Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology (Berl). 2018;235(2):535-545. https://doi.org/10.1007/s00213-017-4733-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/aba0f794-9cd2-4028-91bd-e160498e3de4/study-3.png Educational Resources - Wellness of the ‘Well’ Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011;25(11):1453-1461. https://doi.org/10.1177/0269881111420188 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/315c2cb3-e37c-4281-8fe4-4097f4f7bfb5/study-4.png Educational Resources - Wellness of the ‘Well’ Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Aday JS, Mitzkovitz CM, Bloesch EK, Davoli CC, Davis AK. Long-term effects of psychedelic drugs: A systematic review. Neurosci Biobehav Rev. 2020;113:179-189. https://doi.org/10.1016/j.neubiorev.2020.03.017 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/026ef490-675a-4541-8185-ca7de2bd8594/study-5.png Educational Resources - Wellness of the ‘Well’ Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol. 2011;25(11):1434-1452. https://doi.org/10.1177/0269881110382466 https://www.harmreductionadvocate.com/educational-resources/event-five-7mcnj-xdlse monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/bc8c0261-967a-4318-a5eb-3937e3b45e19/study-1.png Educational Resources - Spiritual Wellness Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006;187(3):268-283. https://doi.org/10.1007/s00213-006-0457-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5abea818-0490-4f8c-b112-ba69b4cfb74c/study-2.png Educational Resources - Spiritual Wellness Quotation from the abstract of the published study (text from the publisher’s page), highlighted in yellow. Source: Samorini G. The oldest archeological data evidencing the relationship of Homo sapiens with psychoactive plants: a worldwide overview. J Psychedelic Stud. 2019;3(2):63-80. https://doi.org/10.1556/2054.2019.008 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9520f12e-4220-485f-8e15-741f5dd677df/study-3.png Educational Resources - Spiritual Wellness Quotation from the abstract of the published study (text from the publisher’s page), highlighted in yellow. Source: Winkelman M. Introduction: evidence for entheogen use in prehistory and world religions. J Psychedelic Stud. 2019;3(2):43-62. https://doi.org/10.1556/2054.2019.024 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f0322888-d490-46ae-a6f7-be2df00a46e4/study-4.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Rodríguez Arce JM, Winkelman MJ. Psychedelics, sociality, and human evolution. Front Psychol. 2021;12:729425. https://doi.org/10.3389/fpsyg.2021.729425 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3775cee2-5b78-4684-9eed-c1eee493848b/study-5.png Educational Resources - Spiritual Wellness Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Rick JW, Lema VS, Echeverría J, et al. Pre-Hispanic ritual use of psychoactive plants at Chavín de Huántar, Peru. Proc Natl Acad Sci U S A. 2025;122(19):e2425125122. https://doi.org/10.1073/pnas.2425125122 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f05eacd5-f4a3-41c2-a91c-7bade797f2c3/study-n26.png Educational Resources - Spiritual Wellness Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Barrett FS, Griffiths RR. Classic hallucinogens and mystical experiences: phenomenology and neural correlates. Curr Top Behav Neurosci. 2018;36:393-430. https://doi.org/10.1007/78542017474 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2265b41f-9ed1-4538-8cf3-aaf1a56a1c64/Screen+Shot+2024-01-22+at+3.31.34+PM.png Educational Resources - Spiritual Wellness - Make it stand out Hartman S. Researchers are giving religious leaders psychedelic drugs in the interest of science. Quartz. January 6, 2017. https://qz.com/879285/psilocybin-drug-trials-psychedelics-such-as-acid-lsd-might-not-only-make-us-more-spiritual-and-religious-they-make-us-healthier-too. Screenshot of the article’s pull quote. Quartz does not name the survey behind this line; a large published comparison of the two kinds of experience is Study 6 under Key studies below (Griffiths, 2019). https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/23873c85-8f9d-4684-ae74-4f65013542d2/Screen+Shot+2024-01-22+at+3.25.17+PM.png Educational Resources - Spiritual Wellness Hartman S. Researchers are giving religious leaders psychedelic drugs in the interest of science. Quartz. January 6, 2017. https://qz.com/879285/psilocybin-drug-trials-psychedelics-such-as-acid-lsd-might-not-only-make-us-more-spiritual-and-religious-they-make-us-healthier-too. Screenshot of the article’s headline. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f81a161f-c1f3-4d29-b34f-b6c0db2c3bff/study-7.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197. https://doi.org/10.1177/0269881116675513 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ce8da055-ea28-40e9-ad04-bc2de568dff7/study-8.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC). Source: Griffiths RR, Jesse R, Richards WA, et al. Effects of psilocybin on religious and spiritual attitudes and behaviors in clergy from various major world religions. Psychedelic Med (New Rochelle). 2025;3(4):172-191. https://doi.org/10.1089/psymed.2023.0044 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9fd403c0-6308-40a7-a5e8-53225f2c7580/study-9.png Educational Resources - Spiritual Wellness Publisher’s note (title block from Europe PMC). Source: Publisher’s note re: “Effects of psilocybin on religious and spiritual attitudes and behaviors in clergy from various major world religions.” Psychedelic Med (New Rochelle). 2025;3(4):171. https://doi.org/10.1089/psymed.2025.68798.pn https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f03fb838-ac34-42a7-bd43-8b68aa6edd92/study-10.png Educational Resources - Spiritual Wellness Published commentary (text from PubMed Central). Source: Simonsson O, Goldberg SB. The promises and pitfalls of psychedelic use among religious leaders. Psychedelic Med (New Rochelle). 2025;3(4):200-201. https://doi.org/10.1177/28314425251392542 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/21acf6c9-567f-45c3-9010-398ea69133e6/_f94113d4-bb85-4a1b-bfa0-3dcecde01345.jpg Educational Resources - Spiritual Wellness - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/59fb4e59-322d-4be0-8a9f-59047c4be15a/study-11.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Frecska, E., Bokor, P., & Winkelman, M. (2016). The therapeutic potentials of ayahuasca: Possible effects against various diseases of civilization. Frontiers in Pharmacology, 7, 35. https://doi.org/10.3389/fphar.2016.00035 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/95429b48-b874-478f-ba98-cdf544882788/Screen+Shot+2024-01-28+at+8.33.58+PM.png Educational Resources - Spiritual Wellness - Make it stand out Moss C. Did early Christians use psychedelics? The Daily Beast. September 29, 2020. https://www.thedailybeast.com/did-early-christians-use-psychedelics. Screenshot of the article’s headline. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b9baa3b6-af96-415e-af1f-36737174d87f/study-12.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Antonopoulos RK, Dadiotis E, Ioannidis K, et al. Investigating the psychedelic hypothesis of kykeon, the sacred elixir of the Eleusinian Mysteries. Sci Rep. 2026;16(1):8757. https://doi.org/10.1038/s41598-026-39568-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5dc6c928-f9e0-4284-b37e-760cd8335672/Screen+Shot+2024-01-28+at+8.52.12+PM.png Educational Resources - Spiritual Wellness - Make it stand out Margolin M, Hartman S. Jews, Christians, and Muslims are reclaiming ancient psychedelic practices, and that could help with legalization. Rolling Stone. April 23, 2021. https://www.rollingstone.com/culture/culture-features/psychedelics-religion-entheogens-1160408/. Screenshot of the article’s headline. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/21d65f83-5737-41fc-8e38-08eaac10d23f/study-13.png Educational Resources - Spiritual Wellness Quotation from the abstract of the published study (text from the publisher’s page), highlighted in yellow. Source: Arie E, Rosen B, Namdar D. Cannabis and frankincense at the Judahite shrine of Arad. Tel Aviv. 2020;47(1):5-28. https://doi.org/10.1080/03344355.2020.1732046 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9da47766-b5c0-404c-9da4-9790c45b12ee/Screen+Shot+2024-01-22+at+3.15.46+PM.png Educational Resources - Spiritual Wellness - Make it stand out Livni E. Scientists studying psychoactive drugs accidentally proved the self is an illusion. Quartz. February 9, 2018. https://qz.com/1196408/scientists-studying-psilocybin-accidentally-proved-the-self-is-an-illusion. Screenshot of the article’s headline (the article was online and the link working on 27 October 2026). https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/033799e9-f7d5-4146-85cf-c297c3c920c2/study-14.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC). Source: Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol. 2018;32(1):49-69. https://doi.org/10.1177/0269881117731279 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6d7e182d-3bd6-4121-853a-0ff202652e70/study-15.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Nour MM, Evans L, Nutt D, Carhart-Harris RL. Ego-dissolution and psychedelics: validation of the Ego-Dissolution Inventory (EDI). Front Hum Neurosci. 2016;10:269. https://doi.org/10.3389/fnhum.2016.00269 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/b94c416a-9d96-4fc3-bcf9-a111bbe10282/study-16.png Educational Resources - Spiritual Wellness Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019). Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology, 33(9), 1088–1101. https://doi.org/10.1177/0269881119845793 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8ebb3ed2-78f3-4cb2-b8e6-c19d5051c104/study-17.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Roseby W, Kettner H, Roseman L, et al. Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies. Front Psychol. 2025;16:1580663. https://doi.org/10.3389/fpsyg.2025.1580663 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a15f281f-501b-4d95-b8ed-c5c546f7664e/study-18.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ferreira AE, Reis-Pina P. Exploring the role of psychedelic-assisted therapy in enhancing spirituality and mystical experiences in patients with life-threatening illnesses: A systematic review. J Psychosom Res. 2025;189:112020. https://doi.org/10.1016/j.jpsychores.2024.112020 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/91b8fd6d-ac10-477b-827c-f42d91004708/study-19.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Meling D, Egger K, Aicher HD, et al. Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat. J Psychopharmacol. 2024;38(10):897-910. https://doi.org/10.1177/02698811241282637 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ca7a7a68-01bd-4673-8460-ad5d526f90b6/study-20.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ko K, Knight G, Rucker JJ, Cleare AJ. Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review. Front Psychiatry. 2022;13:917199. https://doi.org/10.3389/fpsyt.2022.917199 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/55698984-4f86-4437-bab8-809f3124e15c/study-21.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Smigielski L, Kometer M, Scheidegger M, et al. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Sci Rep. 2019;9(1):14914. https://doi.org/10.1038/s41598-019-50612-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1ec796e4-7c1e-4d61-9813-0dae912cb808/study-22.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Griffiths RR, Hurwitz ES, Davis AK, Johnson MW, Jesse R. Survey of subjective “God encounter experiences”: comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLoS One. 2019;14(4):e0214377. https://doi.org/10.1371/journal.pone.0214377 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/cafbaf30-b4a1-4f6f-94a8-0ee8dc700d80/study-23.png Educational Resources - Spiritual Wellness Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165-1180. https://doi.org/10.1177/0269881116675512 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/077105f0-b199-47bb-83a6-69a2f2f5a543/study-24.png Educational Resources - Spiritual Wellness Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011;25(11):1453-1461. https://doi.org/10.1177/0269881111420188 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/36451eb6-7869-466e-99dd-a15ebdceaafb/study-25.png Educational Resources - Spiritual Wellness Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Griffiths RR, Richards WA, Johnson MW, McCann UD, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008;22(6):621-632. https://doi.org/10.1177/0269881108094300 https://www.harmreductionadvocate.com/educational-resources/event-one-8katj monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/8fc359b2-4c8c-4b36-a66b-2d6fa3004e72/_2e4e6650-1c11-4d3d-83ce-53425e9d4479.jpg Educational Resources - Educational Resources: Introduction - A New Era - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/9686bf48-8ac0-4804-b3d0-d117d7d0ae1f/Screenshot+2024-03-09+193517.png Educational Resources - Educational Resources: Introduction - A New Era - Make it stand out Screenshot (9 March 2024): Canadian Drug Policy Coalition, ‘History of Drug Policy in Canada’. https://drugpolicy.ca/resources/guides/history/ https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2bf25c04-d980-468c-9003-ec2cee8a153b/Screenshot+2024-03-09+193727.png Educational Resources - Educational Resources: Introduction - A New Era - Make it stand out Screenshot (9 March 2024): Canadian Drug Policy Coalition, ‘History of Drug Policy in Canada’. https://drugpolicy.ca/resources/guides/history/ https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/a8af6b2d-d3b3-4a8f-a902-c3ead3b4bf41/Screenshot+2024-03-09+201023.png Educational Resources - Educational Resources: Introduction - A New Era - Make it stand out Screenshot (9 March 2024): Canadian Drug Policy Coalition, ‘History of Drug Policy in Canada’. https://drugpolicy.ca/resources/guides/history/ https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/6dfc98ba-36a8-44a1-bd38-a1d6c70e6719/Screenshot+2024-03-09+201137.png Educational Resources - Educational Resources: Introduction - A New Era - Make it stand out Screenshot (9 March 2024): Canadian Drug Policy Coalition, ‘History of Drug Policy in Canada’. https://drugpolicy.ca/resources/guides/history/ https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f36d844f-1525-41ab-83f2-c631e5136706/Screenshot+2024-03-09+201911.png Educational Resources - Educational Resources: Introduction - A New Era - Make it stand out Screenshot (9 March 2024): Canadian Drug Policy Coalition, ‘History of Drug Policy in Canada’. https://drugpolicy.ca/resources/guides/history/ https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/11f976be-ffa0-4896-9abf-ca44def15ee2/study-n5.png Educational Resources - Educational Resources: Introduction - A New Era Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dishotsky NI, Loughman WD, Mogar RE, Lipscomb WR. LSD and genetic damage. Science. 1971;172(3982):431-440. https://doi.org/10.1126/science.172.3982.431 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/5218d3af-6570-4188-af7a-e1d7a3840517/study-n6.png Educational Resources - Educational Resources: Introduction - A New Era Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864. https://doi.org/10.1001/archpsyc.63.8.856 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2b1b6965-dadf-43d6-b365-c3e104fed0a4/study-n1.png Educational Resources - Educational Resources: Introduction - A New Era Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006;187(3):268-283. https://doi.org/10.1007/s00213-006-0457-5 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4c9850f1-7d6c-48cd-8013-0f6f061d2c09/study-n2.png Educational Resources - Educational Resources: Introduction - A New Era Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025-1033. https://doi.org/10.1038/s41591-021-01336-3 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2f01f1f8-7e91-4919-9e5f-4b92e7cfb009/study-n3.png Educational Resources - Educational Resources: Introduction - A New Era Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481-489. https://doi.org/10.1001/jamapsychiatry.2020.3285 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/ec6e0a23-ef59-4768-b58c-ef9004a60c45/study-n4.png Educational Resources - Educational Resources: Introduction - A New Era Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79(10):953-962. https://doi.org/10.1001/jamapsychiatry.2022.2096 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/0244dd06-46f8-4981-a73d-361d6b6acdbf/Screen+Shot+2024-01-22+at+7.34.42+PM.png Educational Resources - Educational Resources: Introduction - A New Era - Make it stand out Cohen A, Vakharia SP, Netherland J, Frederique K. How the war on drugs impacts social determinants of health beyond the criminal legal system. Ann Med. 2022;54(1):2024-2038. https://doi.org/10.1080/07853890.2022.2100926 (free full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC9302017/) https://www.harmreductionadvocate.com/educational-resources/event-five-7mcnj monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2eb91f7e-7c58-476e-93a0-55221a25a97b/Screen+Shot+2024-01-17+at+1.41.01+PM.png Educational Resources - Substance Use Disorder - Make it stand out Nordqvist, C. (2010, November 1). Alcohol is most harmful drug, followed by heroin and crack. Medical News Today. Archived copy: https://web.archive.org/web/20101103201423/http://www.medicalnewstoday.com/articles/206300.php https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/aeae01bd-6adf-486d-bf24-9c9fbf239f5d/Screen+Shot+2024-01-17+at+12.40.57+PM.png Educational Resources - Substance Use Disorder - Make it stand out The Economist Newspaper. (2019, June 25). What is the most dangerous drug?. The Economist. https://www.economist.com/graphic-detail/2019/06/25/what-is-the-most-dangerous-drug https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/64083c48-07fb-45ea-b995-6ac96d4d0cab/Screen+Shot+2024-01-17+at+1.27.10+PM.png Educational Resources - Substance Use Disorder - Make it stand out Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 142, 143–166. https://doi.org/10.1016/j.neuropharm.2018.05.012 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/3aebb4e7-a765-42e6-ab14-0506167361e8/Screen+Shot+2024-01-17+at+2.14.05+PM.png Educational Resources - Substance Use Disorder - Make it stand out Alcohol most harmful drug based on multicriteria analysis: Imperial News: Imperial College London. Imperial News. (2010, November 1). https://www.imperial.ac.uk/news/94042/alcohol-most-harmful-drug-based-multicriteria/ https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/da4bc10c-0044-4014-b466-700e6d7cea7d/study-1.png Educational Resources - Substance Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Nutt DJ, King LA, Phillips LD; Independent Scientific Committee on Drugs. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376(9752):1558-1565. https://doi.org/10.1016/S0140-6736(10)61462-6 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/7ea165f0-e833-4ac1-b983-e0142842155e/Screen+Shot+2024-01-17+at+2.37.33+PM.png Educational Resources - Substance Use Disorder - Make it stand out Data source is the March 24, 2007 article: Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007). Development of a rational scale to assess the harm of drugs of potential misuse. The Lancet, 369(9566), 1047–1053. https://doi.org/10.1016/s0140-6736(07)60464-460464-4) https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/dbf55772-c898-4efe-bab8-b2eac5d5c10c/study-2.png Educational Resources - Substance Use Disorder Excerpt from the full text of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Frecska E, Bokor P, Winkelman M. The therapeutic potentials of ayahuasca: possible effects against various diseases of civilization. Front Pharmacol. 2016;7:35. https://doi.org/10.3389/fphar.2016.00035 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/4679c9a6-031f-4efc-beac-7ceec077dbbb/study-3.png Educational Resources - Substance Use Disorder Excerpt from the full text of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Fang SP, Yang X, Zhao DC, et al. Ketamine for substance use disorders: a systematic review and meta-analysis. Front Psychiatry. 2026;17:1835709. https://doi.org/10.3389/fpsyt.2026.1835709 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/31f02e83-4244-46d3-a594-7b0c10759b06/study-4.png Educational Resources - Substance Use Disorder Excerpt from the full text of the published study (text from Europe PMC). Source: Hendricks PS, Lappan SN, Shelton RC, et al. Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2026;9(5):e2611029. https://doi.org/10.1001/jamanetworkopen.2026.11029 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1c2a0478-f3d3-4acf-ab69-d5dee7b41cf7/study-5.png Educational Resources - Substance Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Piper T, Small F, Brown S, et al. Psychedelic-assisted treatment for substance use disorder: A narrative systematic review. Addiction. 2025. https://doi.org/10.1111/add.16762 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/12315036-6e24-4fe6-9073-b3114f96b099/study-6.png Educational Resources - Substance Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Dakwar E, Nunes EV, Hart CL, et al. A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. Am J Psychiatry. 2019;176(11):923-930. https://doi.org/10.1176/appi.ajp.2019.18101123 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/10126d4f-3188-424b-8ca9-7bf2c708ba10/study-7.png Educational Resources - Substance Use Disorder Quotation from the abstract of the published study (text from Europe PMC), highlighted in yellow. Source: Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983-992. https://doi.org/10.1177/0269881114548296 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/59ecdc22-f8cc-4a0a-9df8-051d975a8c16/study-8.png Educational Resources - Substance Use Disorder Abstract of the published study (text from Europe PMC), key sentence highlighted in yellow. Source: Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022;79(10):953-962. https://doi.org/10.1001/jamapsychiatry.2022.2096 https://www.harmreductionadvocate.com/blog daily 0.75 2026-10-27 https://www.harmreductionadvocate.com/blog/blog-post-title-one-h5eer monthly 0.5 2026-10-28 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/687ae6dd-715d-45d8-8917-d13058fcf8af/1.jpg Blog - Changing Perspectives - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.harmreductionadvocate.com/harmreductionadvocate daily 1.0 2026-09-08 https://images.squarespace-cdn.com/content/v1/6329f526dfa8a56dbab40128/daf61717-83ce-44a7-ae7e-491a77d29f50/image-asset.png https://images.squarespace-cdn.com/content/v1/6329f526dfa8a56dbab40128/1a7a9a0d-4bf0-4a04-ad93-ab1f097ca24c/image-asset.png https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1731384090402-81VJ5SXDZXV4Q4NADKMY/unsplash-image-cNL_7gtBTvY.jpg https://images.squarespace-cdn.com/content/v1/6329f526dfa8a56dbab40128/1a7a9a0d-4bf0-4a04-ad93-ab1f097ca24c/image-asset.png https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/1731384034232-MSIGKE7Z18SKG91QHUDB/unsplash-image-5prKIX4JLO0.jpg https://www.harmreductionadvocate.com/about daily 0.75 2026-09-08 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/046e7fd8-fb9c-41f4-bcd7-d43630e72397/3.jpg https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/f13a0dea-90d6-4502-8625-1e20883b1f21/4.jpg https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/2ff5ad9b-d19a-46b2-889c-c2b95804175a/7.jpg https://www.harmreductionadvocate.com/contact daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/services daily 0.75 2026-09-08 https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1618497259178-6XJGK9GR6YAVBQL5L519/20140301_Trade-151_012-2.jpg Services https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1607694583486-2PQT0LQ193RL7MCB6DX4/20140228_Trade+151_0046.jpg Services https://www.harmreductionadvocate.com/terms-of-service daily 0.75 2024-11-12 https://www.harmreductionadvocate.com/for-practicum-supervisors daily 0.75 2026-09-14 https://www.harmreductionadvocate.com/education-and-credentials daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/what-a-pharmacist-adds daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/medication-safety-screening daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/publications-and-contributions daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/harm-reduction-in-practice daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/rural-remote-and-northern-practice daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/two-eyed-seeing daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/practicum-faq daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/about-this-archive daily 0.75 2026-09-08 https://www.harmreductionadvocate.com/sophrodelic-legal-magic-mushroom-retreat daily 0.75 2026-09-08 https://images.squarespace-cdn.com/content/v1/659d9bcf7b7a4100052bdb52/d6bd992a-4e23-44f6-b37c-702e769393f3/cacona.png https://www.harmreductionadvocate.com/sophrodelic-legal-magic-mushroom-retreat/7-day-morning-flow-challenge monthly 0.5 2024-11-18 https://www.harmreductionadvocate.com/sophrodelic-legal-magic-mushroom-retreat/mindful-meditation monthly 0.5 2024-11-18 https://www.harmreductionadvocate.com/sophrodelic-legal-magic-mushroom-retreat/yoga-for-beginners monthly 0.5 2024-11-18 https://www.harmreductionadvocate.com/sophrodelic-legal-magic-mushroom-retreat/v/how-does-sophrology-work monthly 0.5 2026-10-28 https://www.harmreductionadvocate.com/sophrodelic-legal-magic-mushroom-retreat/v/what-is-sophrology monthly 0.5 2026-10-28